Oppenheimer Initiates Coverage On Rani Therapeutics Hldgs with Outperform Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Rani Therapeutics Holdings (NASDAQ:RANI) with an Outperform rating and a price target of $17.
August 02, 2024 | 9:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Rani Therapeutics Holdings with an Outperform rating and a price target of $17.
The initiation of coverage with an Outperform rating and a specific price target of $17 by a reputable analyst from Oppenheimer is likely to positively influence investor sentiment and drive short-term price appreciation for RANI.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100